Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in RXRX.

← Back to Free Index

RXRX

Analysis as of: 2026-03-07

Recursion Pharmaceuticals, Inc.

Recursion is a clinical-stage biotechnology company using an integrated lab, data, and AI platform to discover and develop small-molecule medicines while monetizing collaborations with pharma partners.

ai automation biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Platform proof is the real bottleneck

The upside case is not generic AI-discovery hype. It is turning one encouraging asset and a proprietary lab-data loop into repeatable clinical proof without funding the journey mainly through dilution.

Analysis

Thesis

Recursion is a well-funded platform biotech whose upside comes from turning one encouraging clinical asset and a proprietary lab-data-compute loop into a repeatable asset engine; if it proves that repeatability by 2031, the stock can rerate materially without needing a magical all-wins outcome.

Last Economy Alignment

Value sits in owned data, wet-lab throughput, and embedded workflow rather than seat software, so cheaper cognition helps more than it hurts; the cap is still clinical proof.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

5.9x (from 5 most recent analyses)

Reasoning

This is a repeatability thesis, not a single-readout moonshot. If Recursion converts REC-4881 into a credible registration path, gets another internal asset into human proof, and broadens partner monetization, investors can value it as a small multi-asset biotech with a real discovery engine rather than a cash-burning science project.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The core risk is that Recursion remains a convincing discovery engine but not a proven medicine business. If REC-4881 and follow-on programs fail to create repeatable clinical proof before cash needs return, the company can drift into a dilution-funded, services-heavy equilibrium.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On February 25, 2026, Recursion filed FY2025 results showing 74.7 of revenue, 371.8 of operating cash use, and runway into early 2028.
On February 25, 2026, the company opened a new 300.0 ATM, preserving flexibility but keeping dilution as a live part of the thesis.
Management reiterated 1H26 windows for REC-1245 early data and REC-4881 FDA-pathway feedback; these remain the near-term repricing gates.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.55

They control the lab, the data, and the workflow that can turn cheaper AI thinking into more drug shots on goal. But that edge only matters if the molecules survive clinical and regulatory gates; otherwise the platform stays an expensive promise.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$7.20

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research